Geoffrey Martha on profitable growth
From Medtronic CEO reveals the impacts of tariffs on company · · Fox Business Clips
“For us, right now, the fact that our growth is accelerating and it's profitable growth. It's really profitable growth like from our cardiology business. That gives you a more of a cushion to operate in but it is difficult. You mentioned tariffs. There's been input cost increases like things like fuel has also been an impact, so it does, the good, the fortunate situation for Medtronic is the innovation is at a really good spot, driving a lot of growth and profitable growth which helps us to mitigate some of these challenges that you're pointing out to on the cost line.”
On , Geoffrey Martha, Chairman of the Board & Chief Executive Officer at Medtronic PLC, spoke about profitable growth during Medtronic CEO reveals the impacts of tariffs on company on Fox Business Clips.
About Geoffrey Martha
Geoffrey Martha discussed the impact of tariffs on Medtronic during a June 2026 appearance on Fox Business, stating that the company's growth and innovation provide a cushion against input cost increases and that Medtronic's supply chain is largely U.S.-based, which he said helps its position in discussions with the administration. In May 2026, he spoke with Siemens Healthineers CEO Bernd Montag about the future of healthcare, describing AI as a game changer for interpreting images and personalizing therapy at scale, and noting that collaboration between therapy and imaging companies is becoming more important. Across fiscal 2025 and 2026 earnings calls, Martha reported accelerating organic revenue growth and raised guidance. He highlighted strong performance in cardiac ablation, noting that the company's pulsed field ablation (PFA) franchise grew 71% in the second quarter of fiscal 2026 and was winning share. Martha also discussed the planned separation of Medtronic's diabetes business through an IPO and spin-off, which he said would sharpen focus on core businesses and be immediately accretive to earnings per share. He emphasized increased investment in R&D and sales and marketing, particularly in high-growth areas such as cardiac ablation, renal denervation, and surgical robotics, and stated that the company is entering a period of greater revenue and earnings growth.